DnB Asset Management
RARE icon

DnB Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

DnB Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$231K Buy
+6,920
New +$172K ﹤0.01% 1134
2025
Q4 		– Sell
-17,479
Closed -$526K – 765
2025
Q3 		$526K Buy
17,479
+2,759
+19% +$82.7K ﹤0.01% 671
2025
Q2 		$535K Buy
14,720
+452
+3% +$16.3K ﹤0.01% 646
2025
Q1 		$517K Buy
14,268
+2,136
+18% +$88.9K ﹤0.01% 654
2024
Q4 		$510K Buy
12,132
+1,889
+18% +$93.7K ﹤0.01% 661
2024
Q3 		$569K Sell
10,243
-2,699
-21% -$137K ﹤0.01% 655
2024
Q2 		$532K Buy
12,942
+2,921
+29% +$125K ﹤0.01% 649
2024
Q1 		$468K Buy
+10,021
New +$473K ﹤0.01% 655
2023
Q4 		– Sell
-12,674
Closed -$452K – 664
2023
Q3 		$452K Buy
12,674
+848
+7% +$33.6K ﹤0.01% 637
2023
Q2 		$546K Buy
+11,826
New +$549K ﹤0.01% 632

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

DnB Asset Management's RARE Position: Q2 2026 in Review

DnB Asset Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 6,920 shares worth $231K. The stake represents ﹤0.01% of the portfolio and ranks #1134 among its holdings. This is a return to the name: DnB Asset Management previously reported a position in RARE as recently as Q3 2025.

DnB Asset Management first reported a position in RARE in Q2 2023 and has held it in 10 quarters since. The position peaked at $569K in Q3 2024. 206 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • DnB Asset Management held 6,920 shares of Ultragenyx Pharmaceutical worth $231K as of Q2 2026.
  • Ultragenyx Pharmaceutical was a new DnB Asset Management position in Q2 2026.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of DnB Asset Management's portfolio in Q2 2026, its #1134 holding.
  • DnB Asset Management first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 10 quarters since.
  • DnB Asset Management's Ultragenyx Pharmaceutical position peaked at $569K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on DnB Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.